Sun Pharma and Moebius Medical announce fast track designation granted for MM-II for the treatment of osteoarthritis knee pain

6 September 2024 - Sun Pharma and Moebius Medical announced that the US FDA has granted fast track designation to ...

Read more →

Perspective Therapeutics granted fast track designation for VMT01 for the diagnosis and treatment of MC1R positive melanoma

5 September 2024 - Perspective Therapeutics today announced that the US FDA granted fast track designation for the development of ...

Read more →

Synthekine granted US FDA fast track designation for CD19 CAR-T and orthogonal IL-2 investigational therapy, SYNCAR-001 + STK-009, for the treatment of lupus without lymphodepletion

4 September 2024 - Synthekine today announced that the US FDA has granted fast track designation to SYNCAR-001 + STK-009, ...

Read more →

Innovent receives fast track designation from the US FDA for IBI363 (PD-1/IL-2α bispecific antibody fusion protein) as monotherapy for advanced melanoma

4 September 2024 - Innovent Biologics announced that the US FDA has granted fast track designation to its PD-1/IL-2α bispecific antibody ...

Read more →

Caribou Biosciences announces the FDA has granted fast track designations to CB-010 in refractory SLE and to CB-012 in relapsed or refractory AML

3 September 2024 - Additional FDA designation for CB-010 following earlier RMAT and fast track designations in B-NHL. ...

Read more →

Life Molecular Imaging receives FDA fast track designation for [18F]PI-2620 in Tau PET imaging across three neurodegenerative conditions

28 August 2024 - Life Molecular Imaging is pleased to announce that the US FDA granted fast track designation to [18F]PI-2620 ...

Read more →

FDA grants fast track designation for bexmarilimab

26 August 2024 - Faron Pharmaceuticals today announces that their lead candidate bexmarilimab has been granted fast track designation for the ...

Read more →

BeiGene’s BGB-16673 receives US FDA fast track designation for CLL/SLL

26 August 2024 - Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with ...

Read more →

FDA grants fast track designation to Aveta Biomics’ drug APG-157 for neo-adjuvant treatment of head and neck cancer

22 August 2024 - Aveta Biomics is pleased to announce that the US FDA has granted fast track designation to APG-157, ...

Read more →

Abata Therapeutics receives FDA fast track designation for ABA-101 for the treatment of progressive multiple sclerosis

22 August 2024 - Abata Therapeutics today announced that the US FDA has granted fast track designation for ABA-101 for the ...

Read more →

Clarity receives FDA fast track designation for 64Cu-SAR-bisPSMA

22 August 2024 - Clarity Pharmaceuticals is pleased to announce that the US FDA has granted fast track designation for 64Cu-SAR-bisPSMA ...

Read more →

ReAlta Life Sciences granted FDA orphan drug designation and fast track designation for RLS-0071 for the treatment of steroid-refractory acute graft versus host disease

19 August 2024 - Second clinical indication for RLS-0071 to receive both orphan drug designation and fast track designation, demonstrating the ...

Read more →

Arthrosi Therapeutics receives FDA fast track designation for AR882 in tophaceous gout

19 August 2024 - Arthrosi Therapeutics today announced the US FDA has granted fast track designation to AR882 for the potential ...

Read more →

Accutar Biotechnology receives FDA fast track designation for AC699 in ER positive, HER2 negative breast cancer

14 August 2024 - Accutar Biotechnology announced today that the US FDA has granted the investigation of AC699 a fast track ...

Read more →

Kiromic BioPharma’s Deltacel receives FDA fast track designation

14 August 2024 - Kiromic BioPharma announces that the US FDA has granted fast track designation to Deltacel (KB-GDT-01), the Company’s ...

Read more →